Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study

MET mutations leading to exon 14 skipping (METΔex14) are strong molecular drivers for non–small‐cell lung cancer (NSCLC). Capmatinib is a highly potent, selective oral MET inhibitor that showed clinically meaningful efficacy and a manageable safety profile in a global phase II study (GEOMETRY mono‐1...

Descripción completa

Detalles Bibliográficos
Autores principales: Seto, Takashi, Ohashi, Kadoaki, Sugawara, Shunichi, Nishio, Makoto, Takeda, Masayuki, Aoe, Keisuke, Moizumi, Sanae, Nomura, Satoshi, Tajima, Takeshi, Hida, Toyoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019204/
https://www.ncbi.nlm.nih.gov/pubmed/33506571
http://dx.doi.org/10.1111/cas.14826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019204/
https://www.ncbi.nlm.nih.gov/pubmed/33506571
http://dx.doi.org/10.1111/cas.14826

Ejemplares similares